share_log

Brokers Offer Predictions for Avivagen Inc.'s FY2024 Earnings (OTCMKTS:VIVXF)

Defense World ·  Sep 2, 2022 01:51

Avivagen Inc. (OTCMKTS:VIVXF – Get Rating) – Investment analysts at Zacks Small Cap issued their FY2024 earnings per share (EPS) estimates for Avivagen in a note issued to investors on Wednesday, August 31st. Zacks Small Cap analyst D. Bautz forecasts that the company will earn ($0.02) per share for the year. The consensus estimate for Avivagen's current full-year earnings is ($0.07) per share.

Get Avivagen alerts:

Avivagen Stock Performance

Shares of VIVXF opened at $0.13 on Thursday. The company has a market capitalization of $9.33 million, a price-to-earnings ratio of -1.40 and a beta of 0.13. The stock has a 50 day moving average of $0.14 and a 200 day moving average of $0.15. Avivagen has a 12 month low of $0.12 and a 12 month high of $0.38.

Avivagen (OTCMKTS:VIVXF – Get Rating) last issued its quarterly earnings results on Wednesday, June 15th. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02). The business had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.23 million.

About Avivagen

(Get Rating)

Avivagen Inc, a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr.

Featured Articles

  • Get a free copy of the StockNews.com research report on Avivagen (VIVXF)
  • Could Nike Stock be Oversold, but Still Overvalued?
  • Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
  • Will Royal Caribbean's Broadband Partnership Drive Revenue?
  • Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
  • DocuSign Has Important Issues to Address When it Reports Earnings

Receive News & Ratings for Avivagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avivagen and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment